N-(2-aminophenyl)-4-methoxybenzamide | 103517-57-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-aminophenyl)-4-methoxybenzamide
• 英文别名: N1-(4-methoxybenzoyl)-1,2-benzenediamine
• CAS: 103517-57-3
• 化学式: C₁₄H₁₄N₂O₂
• mdl: MFCD00447040
• 分子量: 242.277
• InChiKey: BDYVCYUXCNZYRW-UHFFFAOYSA-N

物化性质

• 沸点：
  345.1±27.0 °C(Predicted)
• 密度：
  1.245±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(2-aminophenyl)-4-methoxybenzamide 在 亚硝酸特丁酯 作用下， 以 乙腈 为溶剂， 反应 0.25h， 以92%的产率得到1-(4-methoxybenzoyl)-1H-1,2,3-benzotriazole
  参考文献：
  名称：

  亚硝酸叔丁酯介导的氮转移反应：室温下苯并三唑和叠氮化物的合成

  摘要：

  的A转换ö苯二胺为苯并三唑类是用在室温下实现叔丁基亚硝酸盐。优化的条件也非常适合将磺酰基和酰基肼转化为相应的叠氮化物。该协议不需要任何催化剂或酸性介质。在短时间内以优异的产率获得了所需的产物。

  DOI：

  10.1039/c8ob01950a
• 作为产物：
  描述：

  2-硝基苯胺 在 吡啶 、 氢气 、 钯 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 生成 N-(2-aminophenyl)-4-methoxybenzamide
  参考文献：
  名称：

  A journey from benzanilides to dithiobenzanilides: Synthesis of selective spasmolytic compounds

  摘要：

  A series of dithiobenzanilide derivatives was synthesized and each compound was evaluated for its ability to reduce KCl-induced contractions of smooth muscle preparations of the guinea pig. Starting from a recent publication describing benzanilide derivatives as antispasmodic agents, structure-activity guided synthesis was performed to obtain compounds with improved spasmolytic activity. First, compounds with two amide bonds were designed and second, both amide oxygens were replaced by two sp(2) sulfur atoms resulting in dithiobenzanilide derivatives. The most potent antispasmodic dithiobenzanilide 19 showed improved activity with an IC50 value of 0.4 mu M. Moreover, the study also demonstrated that these active compounds were able to antagonize the effect of spasmogens like acetylcholine and phenylephrine and that the activity is not mediated by activation of ATP-dependent potassium channels (K-ATP-channels) or inhibition of endothelial nitric oxide synthase (eNOS). (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.11.043

文献信息

• Antithrombotic agents
  申请人：Eli Lilly and Company

  公开号：US06313122B1

  公开（公告）日：2001-11-06

  This application relates to a compound of formula (I), a pharmaceutically acceptable salt of the compound, or a prodrug thereof, as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.

  这项申请涉及到式(I)的化合物，该化合物的药用盐或其前药，如本文所定义，以及其药物组合物，以及其作为Xa因子抑制剂的用途，以及其制备方法和中间体。
• Benzimidazole compounds and their use as estrogen agonists/antagonists
  申请人：——

  公开号：US20040002524A1

  公开（公告）日：2004-01-01

  This invention relates to compounds, in particular benzimidazoles, that are useful as estrogen agonists and/or antagonists and pharmaceutical uses thereof. The present invention also relates to benzimidazoles that are selective for the ER&bgr; receptor and pharmaceutical uses thereof.

  本发明涉及一种化合物，特别是苯并咪唑，其作为雌激素激动剂和/或拮抗剂具有用途，并且具有药用用途。本发明还涉及对ER&bgr;受体具有选择性的苯并咪唑及其药用用途。
• Preparation of 1,2-substituted benzimidazoles <i>via</i> a copper-catalyzed three component coupling reaction
  作者：Weiguang Yang、Yu Zhao、Zitong Zhou、Li Li、Liao Cui、Hui Luo

  DOI：10.1039/d1ra00650a

  日期：——

  N-substituted o-phenylenediamines, sulfonyl azides and terminal alkynes. Particularly, the intermediate N-sulfonylketenimine occurred with two nucleophilic addition and the sulfonyl group was eliminated via cyclization. In a way, sulfonyl azides and copper catalysts activated the terminal alkynes to synthesize benzimidazoles.

  通过简单搅拌铜催化剂、 N-取代的邻苯二胺、磺酰叠氮化物和末端炔烃的混合物来制备1,2-取代的苯并咪唑。特别是，中间体N-磺酰基烯酮亚胺发生两次亲核加成，并通过环化消除磺酰基。在某种程度上，磺酰叠氮化物和铜催化剂活化末端炔烃以合成苯并咪唑。
• Novel Aminophenyl Benzamide-Type Histone Deacetylase Inhibitors with Enhanced Potency and Selectivity
  作者：Oscar M. Moradei、Tammy C. Mallais、Sylvie Frechette、Isabelle Paquin、Pierre E. Tessier、Silvana M. Leit、Marielle Fournel、Claire Bonfils、Marie-Claude Trachy-Bourget、Jianhong Liu、Theresa P. Yan、Ai-Hua Lu、Jubrail Rahil、James Wang、Sylvain Lefebvre、Zuomei Li、Arkadii F. Vaisburg、Jeffrey M. Besterman

  DOI：10.1021/jm701079h

  日期：2007.11.1

  catalytic site, which led to the design and synthesis of compound 4 with the unusual bis(aryl)-type pharmacophore. SAR studies around this lead resulted in optimization to potent, selective, nonhydroxamic acid HDAC inhibitors.

  人们正在作出巨大的努力来了解HDAC同种型在人类癌症中的作用，并开发具有更好治疗窗的抗肿瘤药。这项工作的一部分是探索与酶催化位点相邻的14 A内部腔，这导致设计和合成具有不寻常的双（芳基）型药效团的化合物4。围绕该铅的SAR研究导致优化了有效的，选择性的，非异羟肟酸HDAC抑制剂。
• Antithrombotic amides
  申请人：Eli Lilly and Company

  公开号：US06610704B1

  公开（公告）日：2003-08-26

  This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermidates thereof.

  本申请涉及一种具有化学式(I)的化合物（或其药用可接受的盐），如本文所定义，以及该化合物的药物组合物，作为Xa因子抑制剂的用途，以及其制备过程和中间体。